Hledání v detailu akcií
Moje portfolio
Nastavit Oblíbené, nastavit Portfolio
Oblíbené tituly
select
NázevNejlepší
nákup
Nejlepší
prodej
Změna
(%)
ČEZ0,00
KB0,00
PKN9292,04-2,45
Msft136,85136,860,38
Nokia4,64,61-0,72
IBM140,77140,8-1,20
Daimler AG47,3847,39-1,73
PFE36,436,41-1,17
17.09.2019 18:18:54
Indexy online
AD Index online
select
AD Index online
 

  • 17.09.2019 17:35:16
Innate Pharma (IPH.PA, Paris)
Poslední obchod Změna (%) Změna (EUR) Objem obchodů (EUR)
7,36 3,23 0,23 2 496 826
R - Real-Time data si mohou aktivovat klienti Patria Plus / Investor Plus ZDE.

 
  • Poslední aktualizace: 17.09.2019
Popis společnosti
Obecné informace
Název společnostiInnate Pharma SA
TickerIPH
Kmenové akcie:Ordinary Shares
RICIPH.PA
ISINFR0010331421
Poslední známé roční výsledky31.12.2018
Poslední známé čtvrtletní výsledky31.03.2019
Počet zaměstnanců k 31.12.2018 195
Akcie v oběhu k 31.12.2018 57 581 525
MěnaEUR
Kontaktní informace
Ulice117 avenue de Luminy, Bp 30191
MěstoMARSEILLE
PSČ13009
ZeměFrance
Kontatní osobaLaure-Hélene Mercier
Funkce kontaktní osobyChief Financial Officer, Executive Vice President, Member of the Executive Committee
Telefon33 430 303 030
Fax33430303000
Kontatní telefon33 430 303 087

Business Summary: Innate Pharma SA is a France-based biopharmaceutical Company that develops drugs for treatment of cancer and inflammatory diseases. The Company identifies and characterizes drug candidates, selects indications and manages the pre-clinical and clinical development of products. Innate Pharma primarily focuses on the development of new therapeutic solutions and monoclonal antibodies for the treatment of cancer, as well as for the treatment of infectious diseases and chronic inflammatory pathologies. The Company develops two categories of immunotherapies: immuno-modulators and cytotoxic antibodies. The Company works in collaboration with Bristol-Myers Squibb for Phase I cancer antibody program and with Novo Nordisk A/S for two antibody programs in inflammation treatment. In February 2014, it acquired full development and commercialization rights to the anti-NKG2A antibody, a immune checkpoint inhibitor ready for Phase II development in oncology from Novo Nordisk.
Financial Summary: BRIEF: For the fiscal year ended 31 December 2018, Innate Pharma SA revenues increased from EUR32.6M to EUR79.9M. Net income applicable to common stockholders totaled EUR3M vs. loss of EUR48.4M. Revenues reflect an increase in demand for the Company's products and services due to favorable market conditions. Net Income reflects Foreign Exchange Gain increase from EUR784K to EUR4.1M (income), Foreign Exchange Loss decrease of 42% to EUR3.9M (expense).
Odvětvová klasifikace
TRBC2012Bio Diagnostics & Testing
RBSS2004Pharmaceuticals - Diversified
MGINDUSTRYBiotechnology & Drugs
MGSECTORHealthcare
NAICSResearch and Development in the Physical, Engineering, and Life Sciences
SICCommercial Physical Research



  • Poslední aktualizace: 17.09.2019
Management společnosti
FunkceJménoVěkVe funkci odVe firmě od
Chairman of the Supervisory BoardHerve Brailly5730.12.2016
Chairman of the Executive Board, Chief Executive OfficerMondher Mahjoubi6030.12.201630.12.2016
Independent Vice Chairman of the Supervisory BoardIrina Staatz-Granzer5923.06.200923.06.2009
Chief Financial Officer, Executive Vice President, Member of the Executive CommitteeLaure-Hélene Mercier4130.12.2016
Executive Vice President Products Portfolio Strategy & Business Development, Member of the Executive BoardYannis Morel4523.06.2017
Executive Vice President, General Manager US, Member of the Executive CommitteeJennifer Butler-11.03.201911.03.2019
Executive Vice President, Chief Medical Officer, Member of the Executive CommitteePierre Dodion63
Senior Vice President, Chief Scientific Officer, Guest Member of the Executive CommitteeEric Vivier-08.01.201808.01.2018